Page 3 - Tadd Wessel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tadd wessel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tadd Wessel Today - Breaking & Trending Today

ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program

(0)
Financing led by Petrichor Healthcare Capital Management strengthens company s global position as a leader in precision oncology and the field of Targeted Radionuclide Therapy
ITM AG announced today the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors. The proceeds will support the expansion of ITM s precision oncology pipeline as well as fund late-stage development and market access activities for lead candidate, n.c.a.
177Lu-Edotreotide, currently in a phase III trial in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Under the terms of the agreement, the loan will convert into shares of ITM in the event of certain future financial or other corporate development transactions. Further details of the financing were not disclosed. ....

David Katona , Nicola Scharrer , Kostenloser Wertpapierhandel , Steffen Schuster , Udoj Vetter , Tadd Wessel , Isotopen Technologien , District Court , Head Of Marketing Communications , Trophic Communications , Deutsche Bank Freiburg , Fortress Investment Group , Head Of Business Development , Petrichor Healthcare Capital Management , Targeted Radionuclide Therapy , Chief Executive Officer , Managing Partner , Managing Director , Orbimed Advisors , Targeted Radionuclide Therapies , Targeted Radionuclide Diagnostics , Precision Oncology , Healthcare Capital Management , Fortress Investment , Executive Board , Registered Office ,

ITM Closes Convertible Loan Financing Totaling EUR90M

ITM Closes Convertible Loan Financing Totaling EUR90M
ITM, a Munich, Germany-based leader in precision oncology and the field of Targeted Radionuclide Therapy, closed a convertible loan financing totaling €90m (USD 109m).
The round was led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors. Under the terms of the agreement, the loan will convert into shares of ITM in the event of certain future financial or other corporate development transactions. In conjunction with the financing, Tadd Wessel, Founder and Managing Partner at Petrichor, will join ITM’s supervisory board. Further details of the financing were not disclosed. ....

Steffen Schuster , Tadd Wessel , Targeted Radionuclide Therapy , Petrichor Healthcare Capital Management , Managing Partner , Chief Executive Officer , Precision Oncology , ஸ்டெஃபென் ஸ்கஸ்டர் , தாதித் வெசெல் , பெட்ரிகோர் சுகாதாரம் மூலதனம் மேலாண்மை , நிர்வகித்தல் கூட்டாளர் , தலைமை நிர்வாகி அதிகாரி , ப்ரிஸிஶந் புற்றுநோயியல் ,

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
Represents Draw of Additional Proceeds from Petrichor Announced in January 2020
IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an amendment to its January 2020 secured convertible note financing agreement with Petrichor Healthcare Capital Management (“Petrichor”) and PTC Therapeutics, Inc. The amendment, closed today, provides for an additional $7.5 million strategic investment from Petrichor and improves terms relative to the original conversion price and interest rate. The Company intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts. ....

United States , Harolda Hurwitz , Joe Burnett , Tadd Wessel , Jacqueline Keller , Company Clearpoint Neuro Navigation System , Clearpoint Neuro Inc , Fortress Investment Group , Exchange Commission , Company Annual Report On Form , Therapeutics Inc , Company Quarterly Report On Form , Applications Of The Company , Company Smartflow , Represents Draw , Additional Proceeds , Petrichor Announced , Clearpoint Neuro , Petrichor Healthcare Capital Management , Drug Delivery , Managing Partner , Securities Act , Current Report , Point Neuro , Clearpoint Neuro Navigation System , Healthcare Capital Management ,